Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza VLP Vaccine · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | - |
| High dose | EXPERIMENTAL | Investigational Influenza VLP Vaccine 60ug/strain |
| TIV | ACTIVE_COMPARATOR | Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced |
| PBS | PLACEBO_COMPARATOR | - |
| Mid dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Influenza VLP Vaccine | BIOLOGICAL | Single dose; 0.5mL |
| TIV | BIOLOGICAL | Trivalent Influenza Vaccine 15ug/strain, commercially licensed |
| Placebo | BIOLOGICAL | phosphate-buffered saline (PBS) |
| Influenza VLP Vaccine (recombinant) | BIOLOGICAL | Single injection Day 0; 0.5mL |
Inclusion Criteria: 1. Healthy male or female \> 60 years of age at the time of the vaccination. 2. Informed consent must be obtained from the subject prior to beginning any study specific procedures indicating that they understand the purpose of this study and are willing to adhere to the procedur...
Influenza VLP Vaccine is an investigational vaccine being developed for the prevention of influenza, including seasonal influenza. It is designed to generate an immune response against the virus. The vaccine is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Influenza VLP Vaccine is being developed by Novavax, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol NVAX. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in healthy adults and older adults.
Influenza VLP Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA or other regulatory agencies. Three Phase 2 trials have been completed, with a total enrollment of 784 participants, but no active trials are currently ongoing.
Influenza VLP Vaccine has completed three Phase 2 clinical trials in the United States. These include NCT00754455, which enrolled 317 healthy adults aged 18 years and older, NCT00903552, which enrolled 221 adults for seasonal influenza, and NCT01014806, which enrolled 467 older adults aged 60 years and above. All trials were completed.
Influenza VLP Vaccine is a virus-like particle vaccine that mimics the structure of the influenza virus to stimulate an immune response. It is designed to present viral antigens to the immune system without causing infection, potentially providing protection against seasonal influenza strains.